Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-48014
Zardavas , D; Meisel , A; Samaras , P; Knuth , A; Renner , C; Pestalozzi , B C; Stenner-Liewen , F (2011). Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Reports in Oncology, 4(1):16-18.
Video (AVI) (Video 1)
Video (AVI) (Video 2)
We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months, and the response is still continuing. Up to now, no data from randomized clinical studies have been published addressing the question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase inhibitors. The case presented here implies that temsirolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology|
|DDC:||610 Medicine & health|
|Deposited On:||06 May 2011 13:15|
|Last Modified:||23 Nov 2012 15:45|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page